CONFIRM HF: Is it safe to replace intravenous iron in patients with chronic heart failure

This study aimed to assess whether iron replacement versus placebo could improve physical activity in patients with chronic heart failure and iron deficiency. 150 patients for the Iron group and 151 patients to placebo were randomized, physical ability was assessed with the 6 minutes walking test. In the group receiving iron improvement in the 11-meter walk test compared to the placebo group was observed. We also observed an improvement in the quality of life. 

Conclusion 

Patients with chronic heart failure often have iron deficiency anemia in addition to a reduction in intestinal iron absorption. This work demonstrated an improvement in both the walk test and quality of life with intravenous iron administration. 

2_piotr_ponikowski
Piotr Ponikowski
2014-08-31

Original title: Effect of ferric carboxymaltose on functional capacity in patients with heart failure and iron deficiency. CONFIRM-HF.

More articles by this author

ODYSSEY LONG TERM: Safety and efficacy of long-term alirocumab

This was a prospective, randomized, controlled study comparing monoclonal antibody alirocumab with placebo in patients with hypercholesterolemia and high cardiovascular risk. At 24 weeks...

LISTEN: Rosuvastatin versus atorvastatin in Japanese diabetic patients

The treatment of hyperlipidemia is useful in primary and secondary prevention of chronic heart disease and stroke, particularly in diabetic patients. Many statins may...

COPPS-2: Colchicine for prevention of post-pericardiotomy syndrome and postoperative atrial fibrillation

180 patients with colchicine 0.5 mg twice daily from 48-72 hs. before surgery versus 180 patients to placebo were randomized. The medication was continued...

ODYSSEY FH I and FH II: Alirocumab in patients with heterozygous familial hypercholesterolemia

The study included patients with a diagnosis of heterozygous familial hypercholesterolemia who were receiving the maximum tolerated dose of randomized statin alirocumab 75 mg...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Transapical TMVR in High Risk Patients: Intrepid 5-Year Outcomes

Moderate to severe mitral valve regurgitation (MR) continues is still a high prevalence condition with bad prognosis, particularly among the elderly with left ventricular...

EMERALD II: Non-Invasive Coronary Anatomy and Physiology (CCTA) in ACS Prediction

Despite steady progress in secondary prevention and medical treatment optimization (OMT), acute coronary syndrome (ACS) remains one of the leading causes of cardiovascular morbimortality....

Impact of Balloon Post-Dilation on the Long-Term Durability of Bioprostheses after TAVR

Balloon post-dilation (BPD) during transcatheter aortic valve replacement (TAVR) allows for the optimization of prosthesis expansion and the reduction of residual paravalvular aortic regurgitation....